This site is intended for healthcare professionals
Glucagon analogue could halt the hypoglycemia faster than oral carbohydrates
Dasiglucagon, a glucagon analogue, appeared to be effective and highly acceptable for patients with type 1 diabetes with non-severe hypoglycemia, as per a study. Although dasiglucagon produced a similar effect on the target range for blood glucose levels compared to oral carbohydrates, dasiglucagon decreased 5 minutes of median time to achieve euglycemia.
Scientists develop a pancreatic beta-cell restoring therapy to treat T1DM
Mice with T1DM were successfully treated using a pancreatic beta-cell restoring therapy. Initially, the Tregs from the mice blood samples were genetically modified to express beta-cell CAR, and pancreas tissue was processed for islet separation. Later both are co-cultured causing CAR Treg cell proliferation. These findings showed the feasibility of treating human conditions.
The Endocrine Society
Longer therapy with puberty delaying medication lowers bone density: Study
The median overall bone density Z-scores were less than 0 for the young transgenders who were using gonadotropin-releasing hormone or estradiol. The bone density Z-score less than 0 suggests a lower bone density in these people than in others of the same age and sex. Also, prolonged therapy with gonadotropin-releasing hormone was linked to a low bone mineral density Z-score.
The Endocrine Society
Post-COVID-19 care should include identifying diabetes and its management
The risk and burden of incident diabetes and incident anti-hyperglycemic drug use were significantly increased in patients with COVID-19 in the post-acute phase, according to a study. The burden and risks of post-acute COVID-19 outcomes increased in a graded pattern based on the severity of COVID-19 the patients experienced in the acute phase.
Growth hormone could improve liver health in patients with NAFLD
Growth hormone improved hepatic health in people with nonalcoholic fatty liver disease (NAFLD) by reducing liver inflammation and fat, as per a study. Low growth hormone levels and high body weight were related to increased rates of NAFLD and nonalcoholic steatohepatitis. Growth hormone was safe and well-tolerated in patients with hepatic impairment.
The Endocrine Society
A glucose meter could soon detect SARS-CoV-2 antibodies
Researchers developed an accurate, simple glucose-meter-based assay using a novel fusion protein to detect SARS-CoV-2 antibodies. This fusion protein contains an IgG antibody and invertase bounded with the viral spike protein. The antibodies present in the patient's sample could bind to the spike protein enabling the display of antibody levels on a glucose meter.
American Chemical Society
Any exercise could help increase the time in range in patients with T1DM
Adults with T1DM had better glycemic control significantly on days they exercised compared to days they were inactive, regardless of exercise type, according to a study. The mean time in range (TIR) was significantly higher in patients with T1DM on exercise days than on sedentary days. Exercise type did not impact the time patients maintained 70-180 mg/dL glucose range.
Primary hyperparathyroidism could increase the risk of fractures and CVD
Patients with primary hyperparathyroidism had a 51%, 45%, and 72% increased risk of hip fractures, cardiovascular events like a heart attack or stroke, and death, respectively, according to a study. However, patients with primary hyperparathyroidism who underwent partial or entire parathyroidectomy experienced a reduced risk of fractures and CVD.
University of Gothenburg
Prediabetes could be independently associated with cardiac disorders
Prediabetes was linked to a 25% increased risk of myocardial infarction and a 45% increased risk of undergoing percutaneous coronary intervention, as per a study. Also, prediabetes doubled the odds of undergoing coronary artery bypass grafting. Prediabetes persisted as an independent risk factor for myocardial infarction even after controlling all the risk factors.
Patient Care Online
COVID-19 is linked to poor outcomes of CVD and structural changes in the brain
People are at higher risk of developing cardiovascular diseases post-COVID-19, including cerebrovascular disorders, cardiac failure, myocarditis and thromboembolic disease. They are also at higher risk of developing diabetes a year later. There is an increased change in markers of cell damage in locations that are operationally linked to the primary olfactory cortex.